Loading stock data…
TAK
$15.72-0.02 (-0.13%)
After Hours$15.61-0.11 (-0.70%)· Last close Jun 9
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Takeda Pharmaceutical Company Limited in the Healthcare sector is trading at $15.72 with a market capitalization of $51.1B. Wall Street consensus targets $20.39 (3 analysts), implying a +29.7% move over the next 12 months. The stock is currently 17% below its 52-week high of $18.90, remaining 1.7% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +29.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$15.72
Potential Downside
35.1%
Whystock Fair Value$10.20
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare di...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$51.11B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
42.57
Beta
Defensive asset. Lower volatility than the S&P 500.
0.10
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
1.48%
Volume
Today's trading volume
4.57M
Recent News
GSK, Takeda and others notch key clinical wins in tough-to-treat diseases
From hepatitis B to melanoma, recent study results show innovative approaches are gaining ground.
Otsuka showcases kidney drug data; Pfizer cuts an AI deal
Voyxact helped preserve kidney function, but left an opening for competing IgAN drugs from Vera and Vertex. Elsewhere, Takeda’s alliance with Innovent paid early dividends and Axsome warded off generic competitors.
Is Takeda Pharmaceutical Company Limited (TAK) Facing Major Legal Risk After U.S. Jury Rules on Generic Drug Delay?
We recently compiled a list of the 8 Best Immunology Stocks to Buy According to Hedge Funds. Takeda Pharmaceutical Company Limited (NYSE:TAK) is one of the best immunology stocks on our list. TheFly reported on May 18 that a federal jury in the U.S. District Court for the District of Massachusetts determined that Takeda Pharmaceutical Company violated […]
Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Monday Trading
Asian equities traded in the US as American depositary receipts opened the trading week sharply high
Takeda Pharmaceutical (TSE:4502) Valuation Check As Short Term Weakness Meets Longer Term Returns
Takeda Pharmaceutical (TSE:4502) is back in focus after recent trading, with the stock closing at ¥5,108 and showing mixed short term moves, including a decline over the past 3 months and over the past month. See our latest analysis for Takeda Pharmaceutical. The recent 1 day share price gain of 0.95% contrasts with a weaker 3 month share price return of a 10.87% decline. The 1 year total shareholder return of 25.93% highlights how dividends have supported longer term investors even as...